Phase II Study on Sintilimab Combined With Docetaxel for Chemotherapy Failure Advanced NSCLC: the SUCCESS Study (SUCCESS)

• ClinicalTrials.gov Identifier: NCT03798743
• Recruitment Status: Completed
• First Posted: January 10, 2019
• Last Update Posted: March 2, 2022
• Sponsor: Hunan Province Tumor Hospital
• Information provided by (Responsible Party): Yongchang Zhang, Hunan Province Tumor Hospital

Tracking Information

• First Submitted Date: January 5, 2019
• First Posted Date: January 10, 2019
• Last Update Posted Date: March 2, 2022
• Actual Study Start Date: January 1, 2019
• Actual Primary Completion Date: December 30, 2021 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: January 23, 2019)

ORR (Overall response rate) [ Time Frame: Approximately 1 years ]

Evaluation of objective response rates in patients with advanced or metastatic non-small cell lung cancer who failed to receive platinum-based dual-drug chemotherapy in response to RECIST 1.1 and in combination with docetaxel and docetaxel

Original Primary Outcome Measures (submitted: January 8, 2019)

ORR [ Time Frame: Approximately 1 years ]

Evaluation of objective response rates in patients with advanced or metastatic non-small cell lung cancer who failed to receive platinum-based dual-drug chemotherapy in response to RECIST 1.1 and in combination with docetaxel and docetaxel

Current Secondary Outcome Measures (submitted: January 23, 2019)

• PFS (progression free survival time) [ Time Frame: Approximately 1 years ]
  Assessment of the disease-free progression of the subject according to RECIST 1.1
• OS (overall survival time) [ Time Frame: Approximately 1 years ]
  Assess the overall survival of the subject according to RECIST 1.1
• DOR (duration of response) [ Time Frame: Approximately 1 years ]
  Assessment of subject's duration of remission according to RECIST 1.1
• DCR (disease control rate) [ Time Frame: Approximately 1 years ]
  Assessment of subject's disease control rate according to RECIST 1.1
• TTR (time to response) [ Time Frame: Approximately 1 years ]
  Assessment of subject's objective response time according to RECIST 1.1

Original Secondary Outcome Measures (submitted: January 8, 2019)

• PFS [ Time Frame: Approximately 1 years ]
  Assessment of the disease-free progression of the subject according to RECIST 1.1
• OS [ Time Frame: Approximately 1 years ]
  Assess the overall survival of the subject according to RECIST 1.1
• DOR [ Time Frame: Approximately 1 years ]
  Assessment of subject's duration of remission according to RECIST 1.1
• DCR [ Time Frame: Approximately 1 years ]
  Assessment of subject's disease control rate according to RECIST 1.1
• TTR [ Time Frame: Approximately 1 years ]
  Assessment of subject's objective response time according to RECIST 1.1

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Phase II Study on Sintilimab Combined With Docetaxel for Chemotherapy Failure Advanced NSCLC: the SUCCESS Study
• Official Title: Single Center, Single Arm Phase II Study on Efficacy Evaluation and Bio-marker Analysis of Sintilimab Combined With Docetaxel for Double Platinum-based Chemotherapy Failure Advanced Non-small Cell Lung Cancer
• Brief Summary: The study aim to Evaluate the combination of ididilimumab and docetaxel alone in the treatment of previous platinum-containing double-drug chemotherapy according to RECIST 1.1Objective remission rate of advanced or metastatic non-small cell lung cancer with negative, driving gene negative (EGFR, ALK, ROS1); (ORR).
• Detailed Description: This study is a single case of syndilizumab plus docetaxel monotherapy in a Chinese-negative late-stage or metastatic non-small cell lung cancer (NSCLC) failed platinum-containing dual-drug chemotherapy. Center, single arm phase II study. In this study, 30 patients with advanced or metastatic non-small cell lung cancer who had failed platinum-containing dual-drug chemotherapy were treated with rituximab plus docetaxel every 3 weeks until disease progression and intolerance. Toxicity, withdrawal of informed consent, death or other cessation of treatment as prescribed by the program, whichever occurs first. The primary end point was the ORR based on RECIS 1.1, which was evaluated by the Independent Imaging Review Board (IRRC). The longest treatment time for ididibizumab is 24 months. An interim analysis will be conducted during the course of the study. The results and reports will be provided to the Independent Data Audit Committee (IDMC), which determines whether the trial is valid based on the valid cut-off value of the trial and whether the study data can be submitted in advance. Make recommendations to the sponsor. Prior to the interim analysis, the IDMC charter will be finalized and approved by IDMC and the sponsor. The responsibilities and related procedures of IDMC members will be defined in the IDMC charter.
• Study Type: Interventional
• Study Phase: Phase 2
• Study Design: Allocation: N/A; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment
• Condition: Non-small Cell Lung Cancer

Intervention

Drug: Sintilimab Combined With Docetaxel

Sintilimab 200mgi.v q3w Docetaxel 75mg/m2 i.v q3w

Other Name: SCD

Study Arms

Experimental: Sintilimab Combined With Docetaxel

Sintilimab Combined With Docetaxel for Double Platinum-based Chemotherapy Failure Advanced Non-small Cell Lung Cancer

Intervention: Drug: Sintilimab Combined With Docetaxel

• Publications *: Zhang Y, Song L, Zeng L, Xiong Y, Liu L, Zhou C, Yang H, Wang Z, Xia Q, Jiang W, Xu Q, Yang N. Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study. BMC Cancer. 2022 Sep 5;22(1):952. doi: 10.1186/s12885-022-10045-0.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: January 8, 2019): 30
• Original Estimated Enrollment: Same as current
• Actual Study Completion Date: March 1, 2022
• Actual Primary Completion Date: December 30, 2021 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Sign written informed consent before any trial-related processes are implemented
• Age ≥ 18 years old and ≤ 75 years old
• Life expectancy exceeds 3 months
• The investigator confirmed at least one measurable lesion according to the RECIST 1.1 standard
• Histological or cytological diagnosis of NSCLC and stage IIIB/IV stage tumors (according to the International Association for the Study of Lung Cancer)Chest tumor staging manual 8th edition judgment) or in multimodal treatment (radiotherapy, surgical resection or radical chemoradiotherapy local treatment)Subjects with relapse or disease progression after treatment for locally advanced disease.

• Subjects must have previously been treated with a platinum-containing dual chemotherapy (carboplatin or cisplatin) regimen for advanced or metastatic tumorsisease progression occurred during or after the period.

  i) receiving maintenance therapy (referring to treatment with no progress after treatment with a platinum-containing dual chemotherapy regimen) and progress Subjects are eligible for inclusion. Ii) treatment of locally advanced disease with platinum-containing adjuvant, neoadjuvant therapy or radical chemoradiotherapy, and completion of treatment Subjects with tumor recurrence or metastasis within 6 months after treatment are eligible.selected.

Iii) administration of platinum-containing adjuvant, neoadjuvant therapy or radical chemoradiotherapy for treatment of locally advanced disease >6 months laterTumor recurrence, and later progressed during or after treatment of a recurrent tumor with a platinum-based regimen Subjects are eligible for inclusion.

• Patients confirmed by histological specimens who are not eligible for EGFR, ALK or ROS1 targeted therapy (with no tumor) EGFR-sensitive mutations and no evidence of ALK, ROS1 gene rearrangement);
• The Eastern Cancer Cooperative Group (ECOG) has a fitness status score of 0 or 1
• Good hematopoietic function, defined as absolute neutrophil count ≥1.5×109/L, platelet count ≥100×109/L, hemoglobin≥90g/L [no blood transfusion or erythropoietin (EPO) within 7 days] Dependency];
• Good liver function, defined as total bilirubin level ≤ normal upper limit (ULN); patients without liver metastases, Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ≤ 1.5 times ULN, alkaline phosphatase ≤ 2.5 times ULN For patients with recorded liver metastases, AST and ALT levels ≤ 5 times ULN;

Exclusion Criteria:

• Small cell lung cancer
• Currently participating in interventional clinical research treatment, or receiving other research medications within 4 weeks prior to the first dose or Used research equipment;
• Previously received the following treatments: anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs or for another stimulus or association a drug that inhibits T cell receptors (eg, CTLA-4, OX-40, CD137);
• Systemic systemic treatment of Chinese patent medicines or immunomodulatory drugs (including thymosin, interferon, interleukin, except for local use of pleural effusion) with anti-lung cancer indications within 2 weeks prior to the first dose, or before the first dose Major surgical treatment within 3 weeks;
• Pulmonary radiation therapy >30 Gy within 6 months prior to first dose
• Completed palliative radiotherapy within 7 days prior to the first dose

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years to 75 Years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: China

Administrative Information

• NCT Number: NCT03798743
• Other Study ID Numbers: SUCCESS
• Has Data Monitoring Committee: Not Provided

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

• IPD Sharing Statement: Not Provided
• Current Responsible Party: Yongchang Zhang, Hunan Province Tumor Hospital
• Original Responsible Party: Wenxiang Wang, Hunan Province Tumor Hospital, Professor
• Current Study Sponsor: Hunan Province Tumor Hospital
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Principal Investigator: Yongchang Zhang, MD; Hunan Cancer Hospital

• PRS Account: Hunan Province Tumor Hospital
• Verification Date: March 2022